Gyre Therapeutics (GYRE) Income towards Parent Company (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Income towards Parent Company of -$9.9 million for Q1 2026, down 364.01% year-over-year from $3.7 million in Q1 2025, and down 6339.24% quarter-over-quarter from $158000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Income towards Parent Company (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Income towards Parent Company for 17 consecutive years, with -$9.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 364.01% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at -$2.2 million (down 118.71% YoY), while the FY2025 annual figure was $11.4 million, down 36.28% from the prior year.
- Income towards Parent Company eased to -$9.9 million in Q1 2026 per GYRE's latest filing, from $158000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $51.6 million in Q2 2022 and bottomed at -$101.0 million in Q4 2023.
- Historically, Income towards Parent Company has averaged -$3.7 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company surged 325.48% — and 2026, when it plunged 364.01%.
- Gyre Therapeutics' Income towards Parent Company stood at -$28.8 million in 2022, then slumped by 250.76% to -$101.0 million in 2023, then jumped by 100.56% to $569000.0 in 2024, then plunged by 72.23% to $158000.0 in 2025, then sank by 6339.24% to -$9.9 million in 2026.
- Business Quant data shows GYRE's Income towards Parent Company at -$9.9 million in Q1 2026, $158000.0 in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.27 Mn |
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | 158,000.00 |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 569,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -100.98 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -28.79 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.99 Mn |
| Sep 30, 2021 | -27.71 Mn |